---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-23-000059"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:11:22.370625+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Curis Q2 net loss $12.0M ($0.12/sh); FDA lifts partial clinical hold on TakeAim Leukemia study

## Summary
- Net loss $12.0M ($0.12/sh) vs $15.9M ($0.17/sh) in Q2 2022; six-month net loss $23.5M ($0.24/sh).
- Revenue $2.2M from Erivedge royalties; R&D expense $10.0M (down 19% YoY), G&A $4.2M (down 18% YoY).
- FDA removed partial clinical hold on emavusertib TakeAim Leukemia study; confirmed RP2D at 300 mg BID.
- Cash, equivalents and investments $77.4M after July registered direct offering ($13.8M net); runway into 2025.
- Updated clinical data from monotherapy and combination studies expected in 2024.

## SEC filing metadata
- accession: 0001108205-23-000059
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000059/0001108205-23-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000059/cris-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-23-000059
- JSON: https://secwatch.observer/filing/0001108205-23-000059.json
- Plain text: https://secwatch.observer/filing/0001108205-23-000059.txt

## Key facts
- Earnings Releases
  CURIS INC reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, Curis, Inc. announced its financial results for the three- and six-month periods ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000059/0001108205-23-000059-index.htm
- Earnings Releases
  CURIS INC reported financial results for six months ended June 30, 2023.
  - Period: six months ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, Curis, Inc. announced its financial results for the three- and six-month periods ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000059/0001108205-23-000059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.